Doustdar said Medicare coverage and the launch of Novo's new obesity pill should help gradually boost prescription volumes and offset lower prices in the U.S.

New approaches to obesity treatment are emerging as scientists target underexplored metabolic pathways with the help of artificial intelligence. Demand for better obesity medicines is rising quickly, ...

Canada is recognized globally for its world-leading obesity care guidelines — yet Canadians continue to struggle to access the very treatment plans we’ve developed. Meanwhile, the same model of care ...

The CagriSema study results are a setback for the Danish drugmaker in its efforts to regain ground lost to Eli Lilly in the obesity-drug market.

HARTFORD, Conn. (WTNH) — Obesity affects millions of Americans and is now recognized as a chronic disease that requires long-term, comprehensive care. With new medications, advanced surgical options, ...

Patients taking a standard dose of CagriSema lost 20.2% of their body weight after 84 weeks, compared with 23.6% for Lilly’s tirzepatide. “The trial did not achieve its primary endpoint of ...